CSafe and BioLife Collaborate on CGT Delivery
Partnership looks to provide supply chain support for products in this sector, ranging from early clinical phase to commercial scale
CSafe, a provider of powered, temperature-controlled air-freight containers for pharmaceuticals, and BioLife Solutions, Inc., a developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) industry, have formed a new partnership to provide a combined global service network to support CGT products, with a focus on enhanced reliability, security, and quality.
BioLife expects to support 10,000-12,000 evo shipments of CGT starting materials and manufactured doses over the next 12 months (evo being its branded cold chain management platform). The new collaboration is expected to offer supply chain options for any CGT product, at any stage of development, from early clinical-phase trials to global commercial scale.
“CSafe is honored to partner with the team at BioLife Solutions, whose range of CGT bioproduction tools and services is peerless in the market. We are excited to merge these exceptional tools and services with our expertise in global, reliable scaled delivery,” says CSafe CEO Patrick Schafer. “CGT is hitting its stride and needs global support. We know how important these therapies are to patients everywhere, and it’s our mission at CSafe to protect every shipment.”
